David Dai
Stock Analyst at UBS
(0.86)
# 3,917
Out of 5,005 analysts
26
Total ratings
30.43%
Success rate
-15.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Downgrades: Neutral | $72 → $97 | $94.29 | +2.87% | 2 | Sep 30, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $23 → $20 | $10.28 | +94.55% | 1 | Sep 23, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $37 → $35 | $15.60 | +124.36% | 2 | Jul 15, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $9.38 | +177.19% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $21.43 | +39.99% | 1 | Jul 1, 2025 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $17 → $2 | $2.34 | -14.53% | 2 | May 16, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $30 → $24 | $5.90 | +306.78% | 2 | May 12, 2025 | |
| NUVL Nuvalent | Upgrades: Buy | $100 | $84.22 | +18.74% | 2 | Mar 14, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $27 → $14 | $9.57 | +46.29% | 2 | Mar 6, 2025 | |
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $34.21 | -29.85% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.64 | +449.45% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $24.00 | +187.50% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $27.64 | +80.90% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $39.82 | +50.68% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.83 | +3,255.30% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $35.65 | +12.20% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.78 | +2,147.19% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.13 | +2,247.42% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $35.40 | +46.89% | 1 | Mar 17, 2020 |
Merus
Sep 30, 2025
Downgrades: Neutral
Price Target: $72 → $97
Current: $94.29
Upside: +2.87%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $10.28
Upside: +94.55%
Syndax Pharmaceuticals
Jul 15, 2025
Maintains: Buy
Price Target: $37 → $35
Current: $15.60
Upside: +124.36%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $9.38
Upside: +177.19%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $21.43
Upside: +39.99%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.34
Upside: -14.53%
Cullinan Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $5.90
Upside: +306.78%
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $84.22
Upside: +18.74%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27 → $14
Current: $9.57
Upside: +46.29%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $34.21
Upside: -29.85%
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $3.64
Upside: +449.45%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $24.00
Upside: +187.50%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $27.64
Upside: +80.90%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $39.82
Upside: +50.68%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.83
Upside: +3,255.30%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $35.65
Upside: +12.20%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.78
Upside: +2,147.19%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.13
Upside: +2,247.42%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $35.40
Upside: +46.89%